A Phase II Study with Vinorelbine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer / 대한암학회지
Journal of the Korean Cancer Association
;
: 690-698, 2000.
Article
in Korean
| WPRIM
| ID: wpr-68520
ABSTRACT
PURPOSE:
To evaluate the efficacy and safety of vinorelbine and carboplatin in advanced non- small-cell lung cancer (NSCLC). MATERIALS ANDMETHODS:
Between August 1998 and July 1999, 25 patients were enrolled. The median age was 68 (range, 46~77) years and malefemale ratio was 232. Two patients had stage IIIa, 15 had stage IIIb and 8 had stage IV. Sixteen patients had ECOG performance status of 0 or 1 and 9 had 2 or 3. Sixteen patients had squamous cell carcinoma, 8 had adenocarcinoma and 1 had undifferentiated NSCLC. Treatment consists of intravenous carboplatin 400 mg/m2 on day 1 and vinorelbine 25 mg/m2 on days 1 and 8. The treatment was repeated every 28 days.RESULTS:
Twenty-three of 25 patients were evaluable. Partial response were observed in 11 patients. The overall response rate was 48% (95% confidence interval 27~69%) and the median response duration was 19 (range 7 ~44 ) weeks. The median survival of 25 patients was 52 (range 3~53 ) weeks. Toxicities were evaluated by WHO criteria. During a total of 108 cycles, granulocytopenia worse than WHO grade 3 occurred in 2%, thrombocytopenia in 4% and anemia in 10%, respectively. Treatment-related death occurred in 1 patient due to sepsis during cytopenic period. Non-hematologic toxicity was minor and easily controlled.CONCLUSION:
A combination chemotherapy of intravenous vinorelbine and carboplatin has relatively high activity with acceptable toxicities in patients with advanced NSCLC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thrombocytopenia
/
Carcinoma, Squamous Cell
/
Adenocarcinoma
/
Carboplatin
/
Carcinoma, Non-Small-Cell Lung
/
Sepsis
/
Agranulocytosis
/
Drug Therapy
/
Drug Therapy, Combination
/
Anemia
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Cancer Association
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS